Hubei Jumpcan Pharmaceutical Co Ltd (600566) — Net Asset Quality Index
Hubei Jumpcan Pharmaceutical Co Ltd (600566) has a Net Asset Quality Index of 83.8% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥16.53 Billion minus total liabilities of CN¥2.68 Billion yields net assets of CN¥13.86 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Hubei Jumpcan Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hubei Jumpcan Pharmaceutical Co Ltd Net Asset Quality Index Over Time (1998–2024)
This chart shows how Hubei Jumpcan Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 27 annual periods from 1998 to 2024. As of September 2025, the index stands at 83.8%, representing net assets of CN¥13.86 Billion against total assets of CN¥16.53 Billion CNY. See 600566 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Hubei Jumpcan Pharmaceutical Co Ltd (1998–2024)
The table below presents the year-by-year Net Asset Quality Index for Hubei Jumpcan Pharmaceutical Co Ltd from 1998 to 2024, covering 27 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Hubei Jumpcan Pharmaceutical Co Ltd.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 79.8% | CN¥14.73 Billion | CN¥18.46 Billion | CN¥3.73 Billion | ▲ +6.1 pp |
| 2023 | 73.7% | CN¥13.37 Billion | CN¥18.14 Billion | CN¥4.77 Billion | ▼ -2.1 pp |
| 2022 | 75.8% | CN¥11.35 Billion | CN¥14.98 Billion | CN¥3.63 Billion | ▲ +0.5 pp |
| 2021 | 75.3% | CN¥9.13 Billion | CN¥12.13 Billion | CN¥3.00 Billion | ▲ +1.4 pp |
| 2020 | 73.8% | CN¥7.76 Billion | CN¥10.52 Billion | CN¥2.75 Billion | ▲ +3.4 pp |
| 2019 | 70.5% | CN¥6.10 Billion | CN¥8.66 Billion | CN¥2.56 Billion | ▲ +0.5 pp |
| 2018 | 70.0% | CN¥5.46 Billion | CN¥7.80 Billion | CN¥2.34 Billion | ▲ +3.9 pp |
| 2017 | 66.1% | CN¥4.40 Billion | CN¥6.66 Billion | CN¥2.26 Billion | ▼ -7.9 pp |
| 2016 | 73.9% | CN¥3.69 Billion | CN¥4.99 Billion | CN¥1.30 Billion | ▼ -1.7 pp |
| 2015 | 75.7% | CN¥2.71 Billion | CN¥3.59 Billion | CN¥872.59 Million | ▲ +7.3 pp |
| 2014 | 68.3% | CN¥2.29 Billion | CN¥3.36 Billion | CN¥1.06 Billion | ▲ +11.1 pp |
| 2013 | 57.2% | CN¥1.15 Billion | CN¥2.01 Billion | CN¥862.04 Million | ▲ +7.8 pp |
| 2012 | 49.4% | CN¥490.80 Million | CN¥992.87 Million | CN¥502.07 Million | ▼ -5.3 pp |
| 2011 | 54.8% | CN¥526.82 Million | CN¥961.82 Million | CN¥435.00 Million | ▼ -5.5 pp |
| 2010 | 60.3% | CN¥520.27 Million | CN¥863.16 Million | CN¥342.89 Million | ▼ -1.1 pp |
| 2009 | 61.3% | CN¥512.85 Million | CN¥836.22 Million | CN¥323.37 Million | ▲ +0.3 pp |
| 2008 | 61.0% | CN¥506.18 Million | CN¥829.61 Million | CN¥323.43 Million | ▼ -1.2 pp |
| 2007 | 62.2% | CN¥498.83 Million | CN¥802.32 Million | CN¥303.49 Million | ▲ +0.4 pp |
| 2006 | 61.8% | CN¥485.82 Million | CN¥786.51 Million | CN¥300.69 Million | ▼ -3.8 pp |
| 2005 | 65.6% | CN¥480.25 Million | CN¥732.21 Million | CN¥251.96 Million | ▼ -2.3 pp |
| 2004 | 67.9% | CN¥473.92 Million | CN¥697.90 Million | CN¥223.98 Million | ▼ -3.8 pp |
| 2003 | 71.7% | CN¥466.47 Million | CN¥650.39 Million | CN¥183.92 Million | ▼ -3.9 pp |
| 2002 | 75.6% | CN¥459.05 Million | CN¥607.22 Million | CN¥148.17 Million | ▼ -1.6 pp |
| 2001 | 77.2% | CN¥449.57 Million | CN¥582.65 Million | CN¥133.08 Million | ▲ +14.5 pp |
| 2000 | 62.7% | CN¥140.01 Million | CN¥223.38 Million | CN¥83.37 Million | ▼ -1.1 pp |
| 1999 | 63.8% | CN¥125.46 Million | CN¥196.69 Million | CN¥71.23 Million | ▲ +5.6 pp |
| 1998 | 58.2% | CN¥108.44 Million | CN¥186.23 Million | CN¥77.79 Million | — |